LIXTE Biotechnology Advances Ovarian Cancer Trial and Proton Therapy

LIXTE Biotechnology Holdings (NASDAQ: LIXT) is advancing its oncology pipeline with promising updates from its first-quarter 2026 Form 10-Q filing. The company reported the expansion of its ovarian cancer trial for lead candidate LB-100, following favorable safety findings when combined with immunotherapy. LB-100, a first-in-class PP2A inhibitor, is being studied for its potential to enhance chemotherapies and immunotherapies. Additionally, LIXTE highlighted continued growth at its recently acquired Liora Technologies Europe subsidiary, which is developing the LiGHT System—an electronically controlled proton therapy platform for treating tumors. This dual-pronged approach positions LIXTE as a key player in both drug development and advanced radiation therapy.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new cancer drug targets. Its lead compound, LB-100, targets a novel mechanism called activation lethality, aiming to improve outcomes for patients with various cancers. The company is also making strides in proton therapy through Liora Technologies, whose LiGHT System is believed to offer significant advantages over current technologies. With proof-of-concept trials underway for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma, LIXTE is expanding its footprint in oncology. The company’s comprehensive patent portfolio and pioneering research underscore its commitment to transforming cancer treatment. For more details, visit the company’s newsroom at https:/ibn.fm/LIXT.

InvestorWire (IW) distributed this press release, providing enhanced visibility through its network. IW is one of over 75 brands within the Dynamic Brand Portfolio @ IBN, offering services like press release syndication, editorial syndication to 5,000+ outlets, and social media distribution. This coverage helps companies like LIXTE reach investors and the public effectively.